Reviewer’s report

Title: gammaH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

Version: 2  Date: 2 June 2014

Reviewer: Hatim Allawi

Reviewer’s report:

1- The authors submit a well planned experimental evaluation of the effect of combination therapy of the Chk1 inhibitor V158411 with a number of cytotoxic chemotherapeutic agent. They use p53 mutant colon cancer cell line for in vitro testing of the effect of V158411 combo therapy.

2- Data is clear and results are well documented and the manuscript is easy to follow and is well written.

3- More background on the choice of colon cell lines as a model would be helpful.

4- Some explanation of the chemical properties of V158411 (i.e, source, structural features, purity level, etc.) that would not compromise any confidential information would be beneficial to the reader.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

No to all. I declare that I have no competing interests.